SUPRIYA Supriya Lifescience Q2 FY26 results (Jul–Sep 2025) and concall
Supriya Lifescience delivered a strong Q2 FY26, recovering from a muted Q1 with robust sequential and year-on-year revenue growth. The company maintained healthy EBITDA margins and is confident in achieving its full-year guidance, driven by new product launches, backward integration, and the upcoming commercialization of the Ambernath facility. Progress on key projects like DSM and the new API pipeline is on track, positioning the company for sustained growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 20.5%, net profit up 8.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 | 200 +20% |
| EBITDA | 65 | 66 | 68 | 52 | 73 +12% |
| Net profit | 46 | 47 | 50 | 35 | 50 +9% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
